Foamix Pharmaceuticals (NASDAQ:FOMX) is scheduled to post its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect Foamix Pharmaceuticals to post earnings of ($0.28) per share for the quarter.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.04). Foamix Pharmaceuticals had a negative return on equity of 79.46% and a negative net margin of 2,115.11%. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.95 million. On average, analysts expect Foamix Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ FOMX opened at $2.35 on Wednesday. Foamix Pharmaceuticals has a 1 year low of $1.97 and a 1 year high of $7.60. The stock’s 50 day moving average price is $2.40. The firm has a market capitalization of $114.84 million, a price-to-earnings ratio of -1.38 and a beta of 1.63.
A number of brokerages have weighed in on FOMX. HC Wainwright set a $55.00 price target on shares of Acer Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 28th. Zacks Investment Research upgraded shares of Northern Oil & Gas from a “sell” rating to a “hold” rating in a report on Wednesday. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a report on Tuesday, June 11th. ValuEngine lowered shares of Xylem from a “buy” rating to a “hold” rating in a report on Tuesday, May 14th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, May 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $13.96.
In other Foamix Pharmaceuticals news, Director Anna Kazanchyan sold 10,600 shares of Foamix Pharmaceuticals stock in a transaction on Monday, May 20th. The shares were sold at an average price of $2.61, for a total value of $27,666.00. Following the transaction, the director now owns 55,955 shares in the company, valued at approximately $146,042.55. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 16,353 shares of company stock worth $41,153. 2.95% of the stock is owned by company insiders.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Featured Story: Options Trading – Understanding Strike Price
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.